LGVN News and Press, Longeveron Inc. From 12/19/22

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Last Wednesday, we finally got the announcement: Elon Musk had sold another $3.6 billion of Tesla (NASDAQ: TSLA ) stock earlier in the week. (SEC filings tend to lag several days behind transactions). Such a sale had ...

MIAMI, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced that Company leadership will participate in three upcoming investor conferen...

Longeveron Inc. (LGVN) Q3 2022 Earnings Conference Call November 14, 2022 08:30 a.m. ET Company Representatives Dr. Chris Min - Interim Chief Executive Officer, Chief Medical Officer Dr. Joshua Hare - Co-Founder, Chief Science Officer, Chairman James Clavijo - Ch...

Longeveron press release ( NASDAQ: LGVN ): Q3 GAAP EPS of -$0.25 misses by $0.03 . Revenue of $0.3M (+50.0% Y/Y) beats by $0.2M . Cash and short-term investments was $22.3M and $35.0M as of September 30, 2022, and December 31, 2021, respectively. Financ...

-- Achieved key clinical and regulatory milestones across clinical pipeline, including the completion of enrollment in Longeveron’s Phase 2a trial for Alzheimer’s Disease -- -- Conference call scheduled for 8:30 a.m. ET today -- MIAMI, Nov. 14, 2022 (GLOBE NEWS...

MIAMI, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced the completion of enrollment in its Phase 2a trial of Lomecel-B TM in pa...

MIAMI, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced that the Company will release its third quarter 2022 financial results on Mo...

Summary Today, we take our first look at Longeveron Inc., a small clinical-stage biotech concern. The company is targeting multiple disease indications within its pipeline, including Alzheimer's. An investment analysis follows in the paragraphs below. For...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips In October 2021, I made a big call on Longeveron (NASDAQ: LGVN ) stock, a biotech firm working on a promising Alzheimer’s therapy. Within six weeks, shares had risen over 11x… a stunning 1,000% return! ...

MIAMI, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today that Chris Min, M.D., Ph.D., Interim Chief Executive Officer, and Chief Medi...